| Bioactivity | SIRT6-IN-2 (Compound 5) is a selective SIRT6 inhibitor (IC50: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and increases glucose uptake in cultured cells. SIRT6-IN-2 also reduces T cell proliferation. SIRT6-IN-2 has immunosuppressive and chemosensitizing effects[1]. | ||||||||||||
| Target | SIRT6 | ||||||||||||
| Name | SIRT6-IN-2 | ||||||||||||
| CAS | 891002-11-2 | ||||||||||||
| Formula | C19H14N2O6 | ||||||||||||
| Molar Mass | 366.32 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Damonte P, et al. SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects. Bioorg Med Chem. 2017 Oct 15;25(20):5849-5858. |
SIRT6-IN-2
CAS: 891002-11-2 F: C19H14N2O6 W: 366.32
SIRT6-IN-2 (Compound 5) is a selective SIRT6 inhibitor (IC50: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and incr
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.